<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00900718</url>
  </required_header>
  <id_info>
    <org_study_id>CR 03/05</org_study_id>
    <nct_id>NCT00900718</nct_id>
  </id_info>
  <brief_title>Comparison of Straumann Bone Ceramic and Bio-Oss With Guided Tissue Regeneration for Alveolar Ridge Preservation</brief_title>
  <official_title>Comparison of Straumann Bone Ceramic (SBC) and Bio-Oss in Combination With Guided Tissue Regeneration (GTR) for Volume Preservation of Alveolar Ridge After Tooth Extraction: a Randomised, Single Blind, Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Straumann AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Straumann AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare a new biomaterial with an already existing treatment&#xD;
      principle (Bio-Oss/Bio-Gide) with regard to their ability to preserve the dimensions of the&#xD;
      alveolar ridge and to promote bone regeneration and to evaluate the early survival rate of&#xD;
      dental implants placed in the augmented socket area and to assess radiographically and&#xD;
      clinically changes of peri-implant soft and hard tissues.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is prospective, randomized, single-blind, controlled, single center study. The total&#xD;
      study duration for each patient should be 12 +/- 1 month.&#xD;
&#xD;
      In total 13 visits per patient are scheduled in this study.&#xD;
&#xD;
      The study devices Straumann Bone Ceramic and Bio-Oss are CE-marked, and approved by the FDA.&#xD;
      The products are used within the indication.&#xD;
&#xD;
      One center in the Inited Kingdom will participate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The changes of bone level between baseline and 32 week post-extraction</measure>
    <time_frame>baseline and 32 week post-extraction</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>implant success and survival rate</measure>
    <time_frame>1 year post implant loading</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Bone Loss</condition>
  <arm_group>
    <arm_group_label>Straumann Bone Ceramic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bone augmentation, after tooth extraction, with Straumann Bone Ceramic (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bio-Oss</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bone augmentation, after tooth extraction, with Bio-Oss (bovine-derived xenograft)in combination with resorbable collagen membrane Bio-Gide.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Straumann Bone Ceramic</intervention_name>
    <description>Bone augmentation, after tooth extraction, with Straumann Bone Ceramic (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.</description>
    <arm_group_label>Straumann Bone Ceramic</arm_group_label>
    <other_name>Synthetic Bone Substitute</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bio-Oss</intervention_name>
    <description>Bone augmentation, after tooth extraction, with Bio-Oss (bovine-derived xenograft)in combination with resorbable collagen membrane Bio-Gide.</description>
    <arm_group_label>Bio-Oss</arm_group_label>
    <other_name>Xenograft</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient must have voluntarily signed the informed consent&#xD;
&#xD;
          -  Males and females, 18 years to 75 years of age&#xD;
&#xD;
          -  Patient needs single tooth extraction in mandibular or maxillary incisor or pre-molar&#xD;
             region and would benefit from prosthetic reconstruction with a dental implant&#xD;
&#xD;
          -  Patients must be committed to the study and must sign informed consent&#xD;
&#xD;
          -  Patient in good general health as documented by self assessment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Systemic exclusion criteria&#xD;
&#xD;
          -  Patient who has any known diseases (not including controlled diabetes mellitus),&#xD;
             infections or recent surgical procedures within 30 days of study initiation&#xD;
&#xD;
          -  Female patient who are pregnant or lactating or of child bearing potential not using&#xD;
             acceptable methods of birth control (hormonal, barriers or abstinence&#xD;
&#xD;
          -  Patient who are on chronic treatment (i.e., two weeks or more) with any medication&#xD;
             known to affect oral status (e.g., phenytoin, dihydropyridine calcium antagonists,&#xD;
             cyclosporine, and non-steroidal anti-inflammatory drugs) within one month of baseline&#xD;
             visit&#xD;
&#xD;
          -  Patient who are on concomitant anticoagulant therapy of warfarin (coumadine),&#xD;
             clopidogrel, ticlopidine or once daily asprin of more than 81 mg.&#xD;
&#xD;
          -  Patient who knowingly has HIV or Hepatitis&#xD;
&#xD;
          -  Physical handicaps that would interfere with the ability to perform adequate oral&#xD;
             hygiene&#xD;
&#xD;
          -  Patient who has undergone administration of any investigational drug within 30 days of&#xD;
             study initiation.&#xD;
&#xD;
          -  Alcoholism or chronically drug abuse causing systemic compromisation&#xD;
&#xD;
          -  Patient who is a heavy smoker (&gt;10/cigarettes per day).&#xD;
&#xD;
          -  Patient is suffering from a known psychological disorder&#xD;
&#xD;
          -  Patient has limited mental capacity or language skills such that study information&#xD;
             cannot be understood, informed consent cannot be obtained, or simple instructions&#xD;
             cannot be followed&#xD;
&#xD;
        Local exclusion criteria&#xD;
&#xD;
          -  Uncontrolled or untreated periodontal disease&#xD;
&#xD;
          -  Bone defects that excludes implant restoration&#xD;
&#xD;
          -  Patient who has a full mouth plaque level &gt;30 % at the enrolment visit&#xD;
&#xD;
          -  Mucosal diseases such as erosive lichen planus&#xD;
&#xD;
          -  History of local radiation therapy&#xD;
&#xD;
          -  Presence of oral lesions (such as ulceration, malignancy)&#xD;
&#xD;
          -  Severe bruxing or clenching habits&#xD;
&#xD;
          -  Persistent intraoral infection&#xD;
&#xD;
          -  Patients presenting clinical and radiological signs and symptoms of maxillary sinus&#xD;
             disease&#xD;
&#xD;
          -  Patient presents an acute endodontic lesion in the test tooth or in the neighbouring&#xD;
             areas to the experimental procedure (sites with presence of an asymptomatic chronic&#xD;
             lesion are eligible)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nikolaos Donos, DDS, MS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eastman Dental Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eastman Dental Institute, University College London</name>
      <address>
        <city>London</city>
        <zip>WC1X8LD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>May 11, 2009</study_first_submitted>
  <study_first_submitted_qc>May 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2009</study_first_posted>
  <last_update_submitted>March 2, 2016</last_update_submitted>
  <last_update_submitted_qc>March 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

